Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. JSP Pharmaceutical Manufacturing (Thailand) PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.13%.
BKK:JSP's ROC (Joel Greenblatt) % is ranked worse than 55.49% of 1975
companies
in the Consumer Packaged Goods industry
Industry Median: 12.08
vs BKK:JSP: 10.08
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:JSP vs KHC, GIS: ROC (Joel Greenblatt) % Comparison
For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL ROC (Joel Greenblatt) % vs Consumer Packaged Goods Industry
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 2.13% mean?
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a ROC (Joel Greenblatt) % of 2.13% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. This is 79% below median its historical median of 10.34. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1096 out of 1975 companies in the Consumer Packaged Goods industry, placing it in the top 55.5%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC (Joel Greenblatt) % too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current ROC (Joel Greenblatt) % of 2.13% is 79% below median its 10-year median of 10.34. The Consumer Packaged Goods industry median ROC (Joel Greenblatt) % is 12.08. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 2.13% is 82.4% below this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1096 out of 1975 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's ROC (Joel Greenblatt) % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #1096 out of 1975 companies for ROC (Joel Greenblatt) %. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.08. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 2.13% is 82.4% below this benchmark. While the company's 10-year median is 10.34 vs. the industry median of 12.08, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median ROC (Joel Greenblatt) % among Consumer Packaged Goods companies is 12.08, based on 1,975 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current ROC (Joel Greenblatt) % of 2.13% is 82.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median ROC (Joel Greenblatt) % is 12.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current ROC (Joel Greenblatt) % is 2.13%, which is 79% below median its own 10-year median of 10.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.20, compared to a current price of ฿1.80 — trading 43.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 2.13%, which is 79% below median its 10-year median of 10.34 and 82.4% below the Consumer Packaged Goods industry median of 12.08. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current ROC (Joel Greenblatt) % is 2.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.80 is trading 43.8% below its estimated GF Value™ of ฿3.20.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.
Key valuation signals for BKK:JSP:
ROC (Joel Greenblatt) %: 2.13% (79% below median its 10-year median of 10.34)
GF Value™: ฿3.20 vs. price of ฿1.80 (43.8% below fair value)
Industry Position: 82.4% below the Consumer Packaged Goods median (#1096 of 1975)
No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score
Get the complete analysis for BKK:JSP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP has been successfully added to your 
